Milestones

1. Consolidation of the group's transfer activity in biomarkers in gastro-intestinal tumours: i) collaboration with AMADIX, (RETOS-Collaboration project) for diagnostic kit in pancreatic cancer; ii) biomarkers of response in drug repositioning in this tumour, with generic companies (REMEDi4ALL); iii) multimodal biomarkers (miRAmut) prognostic in colorectal cancer, including radiomic markers, in collaboration with Quibim (DTS Project). iv) Collaboration with Radiation Oncology and Medical Oncology. 1 Doctoral Thesis and incorporation of postdoctoral staff.
2. Consolidation of a line of research into biomarkers useful for personalised medicine in clear cell renal carcinoma. Identification of molecular signatures including non-coding RNAs and radiomic parameters predictive of response to new lines of treatment in this tumour context. Collaboration with Medical Oncology and Radiation Oncology (ISCIII Health project and new ISCIII project application). 2 Doctoral theses defended. 1 new competitive pre-doctoral resource (PFIS22)
3. Consolidation as a European reference group in multi-omic and multimodal biomarkers, initiating the development of artificial intelligence tools, through national and European projects such as EATRIS Plus, with leadership in the generation of tools such as MultiomicToolBox (https://motbx.eatris.eu/)
4. Consolidation as a reference group in drug repositioning, through European initiatives and projects such as REMEDi4ALL, in collaboration with policy makers (EU commission), regulatory agencies (EMEA) and patient organisations (PEOF, EURORDIS, POP)
5. Scientific Management of the Spanish Node of the EATRIS Translational Medicine Infrastructure: European positioning of the Spanish Node in EATRIS, made up of 32 of the 35 accredited Institutes, and leadership in initiatives at national and European level on Patient Engagement and Digital Transformation of the Health System.